Reverse signaling contributes to control of chronic inflammation by anti-TNF therapeutics

Orsolya Sipos, Annamária Török, Tanja Kalic, E. Duda, Kata Filkor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Anti-tumor necrosis factor (TNF) monoclonal antibodies and TNF receptor ectodomain fusion protein are in clinical use to neutralize circulating TNF and ameliorate symptoms of many autoimmune diseases and pathological conditions with chronic inflammation. In this paper we present data to prove that reverse signaling, elicited by agonist molecules interacting with the membrane-bound TNF of myeloid cells, significantly contributes to the therapeutic effect of these anti-TNF medicines. Interaction of agonist monoclonals with cell surface TNF significantly attenuates the expression of pro-inflammatory cytokines and induces changes in the production of extracellular and intracellular signaling molecules. This phenomenon is not dependent on the Fc portion of antibodies as Fab constructs are as efficient as full antibody molecules.

Original languageEnglish
Pages (from-to)123-140
Number of pages18
JournalAntibodies
Volume4
Issue number2
DOIs
Publication statusPublished - Jun 9 2015

Fingerprint

Tumor Necrosis Factor-alpha
Inflammation
Therapeutics
Antibodies
Tumor Necrosis Factor Receptors
Therapeutic Uses
Myeloid Cells
Autoimmune Diseases
Monoclonal Antibodies
Cytokines
Membranes
Proteins

Keywords

  • Autoimmune
  • Inflammation
  • Macrophage
  • Monoclonal antibodies
  • Reverse signal
  • TNF receptor
  • Tumor necrosis factor (TNF)

ASJC Scopus subject areas

  • Drug Discovery
  • Immunology
  • Immunology and Allergy

Cite this

Reverse signaling contributes to control of chronic inflammation by anti-TNF therapeutics. / Sipos, Orsolya; Török, Annamária; Kalic, Tanja; Duda, E.; Filkor, Kata.

In: Antibodies, Vol. 4, No. 2, 09.06.2015, p. 123-140.

Research output: Contribution to journalArticle

Sipos, Orsolya ; Török, Annamária ; Kalic, Tanja ; Duda, E. ; Filkor, Kata. / Reverse signaling contributes to control of chronic inflammation by anti-TNF therapeutics. In: Antibodies. 2015 ; Vol. 4, No. 2. pp. 123-140.
@article{4bc0d6f04069461d9f3d6a337f0b68c2,
title = "Reverse signaling contributes to control of chronic inflammation by anti-TNF therapeutics",
abstract = "Anti-tumor necrosis factor (TNF) monoclonal antibodies and TNF receptor ectodomain fusion protein are in clinical use to neutralize circulating TNF and ameliorate symptoms of many autoimmune diseases and pathological conditions with chronic inflammation. In this paper we present data to prove that reverse signaling, elicited by agonist molecules interacting with the membrane-bound TNF of myeloid cells, significantly contributes to the therapeutic effect of these anti-TNF medicines. Interaction of agonist monoclonals with cell surface TNF significantly attenuates the expression of pro-inflammatory cytokines and induces changes in the production of extracellular and intracellular signaling molecules. This phenomenon is not dependent on the Fc portion of antibodies as Fab constructs are as efficient as full antibody molecules.",
keywords = "Autoimmune, Inflammation, Macrophage, Monoclonal antibodies, Reverse signal, TNF receptor, Tumor necrosis factor (TNF)",
author = "Orsolya Sipos and Annam{\'a}ria T{\"o}r{\"o}k and Tanja Kalic and E. Duda and Kata Filkor",
year = "2015",
month = "6",
day = "9",
doi = "10.3390/antib4020123",
language = "English",
volume = "4",
pages = "123--140",
journal = "Antibodies",
issn = "2073-4468",
publisher = "MDPI AG",
number = "2",

}

TY - JOUR

T1 - Reverse signaling contributes to control of chronic inflammation by anti-TNF therapeutics

AU - Sipos, Orsolya

AU - Török, Annamária

AU - Kalic, Tanja

AU - Duda, E.

AU - Filkor, Kata

PY - 2015/6/9

Y1 - 2015/6/9

N2 - Anti-tumor necrosis factor (TNF) monoclonal antibodies and TNF receptor ectodomain fusion protein are in clinical use to neutralize circulating TNF and ameliorate symptoms of many autoimmune diseases and pathological conditions with chronic inflammation. In this paper we present data to prove that reverse signaling, elicited by agonist molecules interacting with the membrane-bound TNF of myeloid cells, significantly contributes to the therapeutic effect of these anti-TNF medicines. Interaction of agonist monoclonals with cell surface TNF significantly attenuates the expression of pro-inflammatory cytokines and induces changes in the production of extracellular and intracellular signaling molecules. This phenomenon is not dependent on the Fc portion of antibodies as Fab constructs are as efficient as full antibody molecules.

AB - Anti-tumor necrosis factor (TNF) monoclonal antibodies and TNF receptor ectodomain fusion protein are in clinical use to neutralize circulating TNF and ameliorate symptoms of many autoimmune diseases and pathological conditions with chronic inflammation. In this paper we present data to prove that reverse signaling, elicited by agonist molecules interacting with the membrane-bound TNF of myeloid cells, significantly contributes to the therapeutic effect of these anti-TNF medicines. Interaction of agonist monoclonals with cell surface TNF significantly attenuates the expression of pro-inflammatory cytokines and induces changes in the production of extracellular and intracellular signaling molecules. This phenomenon is not dependent on the Fc portion of antibodies as Fab constructs are as efficient as full antibody molecules.

KW - Autoimmune

KW - Inflammation

KW - Macrophage

KW - Monoclonal antibodies

KW - Reverse signal

KW - TNF receptor

KW - Tumor necrosis factor (TNF)

UR - http://www.scopus.com/inward/record.url?scp=84977825804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977825804&partnerID=8YFLogxK

U2 - 10.3390/antib4020123

DO - 10.3390/antib4020123

M3 - Article

VL - 4

SP - 123

EP - 140

JO - Antibodies

JF - Antibodies

SN - 2073-4468

IS - 2

ER -